• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Biote Corp. filed SEC Form 8-K: Regulation FD Disclosure

    6/9/25 4:40:16 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $BTMD alert in real time by email
    8-K
    false 0001819253 0001819253 2025-06-05 2025-06-05
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934

    Date of Report (Date of earliest event reported): June 5, 2025

     

     

    biote Corp.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-40128   85-1791125

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

    1875 W. Walnut Hill Ln #100

    Irving, Texas 75038

    (Address of principal executive offices, including zip code)

    (844) 604-1246

    (Registrant’s telephone number, including area code)

    (Former name or former address, if changed since last report)

     

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbols

     

    Name of each exchange on
    which registered

    Class A common stock, par value $0.0001 per share   BTMD   The Nasdaq Stock Market LLC

    Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencements communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 5.02

    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    On June 5, 2025, the Board of Directors (the “Board”) of biote Corp. (the “Company”), following the recommendation of the Nominating and Corporate Governance Committee, appointed Richard R. Barrera to serve as a member of the Board to fill the vacancy created by the prior resignation of Steven J. Heyer and as a member of the Nominating and Corporate Governance Committee, effective immediately. Mr. Barrera is a Class II director whose term will expire at the Company’s 2027 Annual Meeting of Stockholders. The Board has determined that Mr. Barrera is “independent” pursuant to the rules of The Nasdaq Stock Market LLC and other governing laws and applicable regulations.

    Mr. Barrera, age 53, is the Founder and Portfolio Manager of Roystone Capital, a New York based hedge fund. Prior to founding Roystone Capital in 2012, Mr. Barrera was a Partner and Co-Portfolio Manager at Redwood Capital from 2009 to 2012 and Glenview Capital from 2002 to 2009. He began his career as an Analyst at Gleacher & Co., then worked as an Emerging Markets sovereign bond trader at JP Morgan and then at Groupe Arnault’s family office. Mr. Barrera received his Bachelor’s degree in Finance and Accounting from The Wharton School of the University of Pennsylvania and an MBA from the Harvard Business School. We believe Mr. Barrera’s extensive finance, investment and operations experience qualifies him to serve as a member of the Board.

    There is no arrangement or understanding between Mr. Barrera and any other person pursuant to which he was selected as a director, and there is no family relationship between Mr. Barrera and any of the Company’s other directors or executive officers. There are no transactions between Mr. Barrera and the Company that would be required to be reported under Item 404(a) of Regulation S-K.

    As a non-employee director of the Company, Mr. Barrera is eligible to participate in the Company’s non-employee director compensation policy, as amended, pursuant to which he will receive (a) an annual cash base retainer of $50,000 per year for service on the Board and (b) an initial equity award with a grant-date fair value of $337,500. The initial equity award (i) will be made pursuant to the Company’s 2022 Equity Incentive Plan, (ii) will consist of an option to purchase the Company’s Class A common stock, and (iii) will vest in 36 substantially equal monthly installments following the grant date, subject to his continued Board service.

    In addition, on the date of each annual stockholder meeting of the Company, and assuming Mr. Barrera continues to serve as a non-employee member of the Board following such stockholder meeting, Mr. Barrera will automatically be granted an option to purchase shares of the Company’s Class A common stock with a grant date fair value of $216,000 (but prorated to reflect the time between his initial election or appointment date and the date of such first annual stockholder meeting), vesting in full on the earlier of the first anniversary of the grant date or the day prior to the date of the Company’s next following annual stockholder meeting, subject to his continued Board service.

    All of Mr. Barrera’s then-outstanding equity awards granted in connection with the Company’s non-employee director compensation policy, as amended, shall vest and become exercisable in full if the Company is subject to a change in control prior to the termination of his continuous Board service.

    In connection with Mr. Barrera’s election to the Board, the Company and Mr. Barrera entered into the Company’s standard form of indemnification agreement, a copy of which was filed as Exhibit 10. 4 to the Company’s Current Report on Form 8-K (File No. 001-40128), filed with the SEC on June 2, 2022. This agreement requires the Company to indemnify Mr. Barrera, to the fullest extent permitted by Delaware law, for certain liabilities to which he may become subject as a result of his affiliation with the Company.

     

    Item 7.01

    Regulation FD Disclosure.

    On June 9, 2025, the Company issued a press release announcing the appointment of Mr. Barrera to the Board. A copy of the Company’s press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

     


    The information provided in Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. This Current Report on Form 8-K will not be deemed an admission as to the materiality of any information contained in this Item 7.01, including Exhibit 99.1.

     

    Item 9.01.

    Financial Statements and Exhibits.

    (d) Exhibits.

     

    Exhibit

    No.

       Description
    99.1    Press Release dated June 9, 2025
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     


    SIGNATURE

    Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    BIOTE CORP.
    By:  

    /s/ Bret Christensen

    Name:   Bret Christensen
    Title:   Chief Executive Officer

    Date: June 9, 2025

    Get the next $BTMD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BTMD

    DatePrice TargetRatingAnalyst
    12/16/2024Buy
    Craig Hallum
    2/20/2024$9.00Buy
    B. Riley Securities
    2/1/2024Buy
    Jefferies
    More analyst ratings

    $BTMD
    Financials

    Live finance-specific insights

    See more
    • Biote Reports First Quarter 2025 Financial Results

      Strong financial performance driven in part by increased gross margin from vertical integration Announces organizational restructuring to drive sustainable growth and build long-term value Maintains 2025 financial outlook First Quarter 2025 Financial Highlights Revenue of $49.0 million Gross profit margin of 74.3% Net income of $15.8 million and diluted earnings per share attributable to biote Corp. stockholders of $0.37, compared to net loss of $(5.7) million and diluted loss per share attributable to biote Corp. stockholders of $(0.12) in the prior year period Adjusted EBITDA1 of $13.8 million and Adjusted EBITDA margin1 of 28.1% Biote (NASDAQ:BTMD), a leading solutions provi

      5/7/25 4:05:00 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Biote Schedules First Quarter 2025 Financial Results Release and Conference Call

      biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide first quarter financial results on Wednesday, May 7, 2025, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call may be accessed by dialing (844) 481-2820 (U.S toll-free) or (412) 317-0679 (International). The live webcast of the call can be accessed using the following link: biote Corp. First Quarter Earnings Call. A replay of the webcast will be

      4/23/25 4:05:00 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Biote Reports Fourth Quarter and Full Year 2024 Financial Results

      Strengthened business with launch of BioteRx and enhancements to Biote Method Provides fiscal 2025 outlook Biote (NASDAQ:BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights (All financial result comparisons made are against the prior-year period) Revenue of $49.8 million Procedure revenue of $36.6 million Gross profit margin of 71.8% Net income of $3.5 million and diluted earnings per share attributable to biote Corp. stockholders of $0.10, compared to

      3/12/25 4:05:00 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $BTMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Biote Names Rich Barrera to Board of Directors

      biote Corp.(NASDAQ:BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that its Board of Directors has elected Rich Barrera to the Board, effective immediately. "We are pleased to welcome Rich Barrera to Biote's Board of Directors," said Marc Beer, Executive Chairman of Biote. "Rich has a distinguished background as an investment professional, founding Roystone Capital in 2012 and managing investment portfolios for more than 20 years. For the past few years, we've had the pleasure of working with Rich and his team at Roystone, which is one of Biote's top institutional shareholders

      6/9/25 4:05:00 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Biote Reports First Quarter 2025 Financial Results

      Strong financial performance driven in part by increased gross margin from vertical integration Announces organizational restructuring to drive sustainable growth and build long-term value Maintains 2025 financial outlook First Quarter 2025 Financial Highlights Revenue of $49.0 million Gross profit margin of 74.3% Net income of $15.8 million and diluted earnings per share attributable to biote Corp. stockholders of $0.37, compared to net loss of $(5.7) million and diluted loss per share attributable to biote Corp. stockholders of $(0.12) in the prior year period Adjusted EBITDA1 of $13.8 million and Adjusted EBITDA margin1 of 28.1% Biote (NASDAQ:BTMD), a leading solutions provi

      5/7/25 4:05:00 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Biote Schedules First Quarter 2025 Financial Results Release and Conference Call

      biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide first quarter financial results on Wednesday, May 7, 2025, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call may be accessed by dialing (844) 481-2820 (U.S toll-free) or (412) 317-0679 (International). The live webcast of the call can be accessed using the following link: biote Corp. First Quarter Earnings Call. A replay of the webcast will be

      4/23/25 4:05:00 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $BTMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Biote Corp.

      SC 13G/A - biote Corp. (0001819253) (Subject)

      11/12/24 4:15:18 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Biote Corp. (Amendment)

      SC 13G/A - biote Corp. (0001819253) (Subject)

      2/14/24 5:17:02 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Biote Corp. (Amendment)

      SC 13G/A - biote Corp. (0001819253) (Subject)

      2/14/24 2:11:05 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $BTMD
    SEC Filings

    See more
    • Biote Corp. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - biote Corp. (0001819253) (Filer)

      6/9/25 4:40:16 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 8-K filed by Biote Corp.

      8-K - biote Corp. (0001819253) (Filer)

      6/5/25 8:22:07 AM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 8-K filed by Biote Corp.

      8-K - biote Corp. (0001819253) (Filer)

      5/14/25 4:15:31 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $BTMD
    Leadership Updates

    Live Leadership Updates

    See more
    • Biote Announces CEO Retirement and Succession Plan

      Terry Weber Retiring as CEO and Director and Transitioning to Strategic Advisor to Company's Board of Directors Health Care Veteran Bret Christensen to Succeed Terry Weber as CEO and Director biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that Terry Weber is retiring as Chief Executive Officer and stepping down from the Company's Board of Directors, effective as of February 1, 2025. She will be transitioning to Strategic Advisor to the Company's Board of Directors. Concurrently, Mr. Bret Christensen has been named Chief Executi

      1/30/25 4:10:00 PM ET
      $BTMD
      $HOLX
      $MYGN
      $PODD
      Medicinal Chemicals and Botanical Products
      Health Care
      Medical Electronics
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
    • Biote to Purchase Asteria Health

      Strategic and accretive transaction enables vertical integration of hormone product manufacturing biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced a definitive agreement to acquire F.H. Investments, Inc., d/b/a Asteria Health, a privately held 503B manufacturer of compounded bioidentical hormones. The company operates an FDA-registered 503B outsourcing facility in Birmingham, Alabama and currently supports Biote-certified practitioners and Biote-partnered clinics in numerous U.S. states. Through this transaction, Biote is strengt

      1/17/24 4:05:00 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Biote Names Robert Peterson as Chief Financial Officer

      biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that Robert Peterson has been named Chief Financial Officer, effective January 8, 2024. Mr. Peterson will lead Biote's finance operations, including accounting and controllership, financial planning and analysis, financial reporting, internal audit, tax, treasury and investor relations. Mr. Peterson succeeds Samar Kamdar, who is transitioning to pursue other opportunities, but will remain as an advisor to the Company during a transition period. Mr. Kamdar's transition is unrelated to t

      1/11/24 4:05:00 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $BTMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $BTMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Large owner Guines Llc bought $1,461,373 worth of shares (447,714 units at $3.26) (SEC Form 4)

      4 - biote Corp. (0001819253) (Issuer)

      5/8/25 7:16:54 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Large owner Guines Llc bought $6,371 worth of shares (1,933 units at $3.30) (SEC Form 4)

      4 - biote Corp. (0001819253) (Issuer)

      5/2/25 5:12:33 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Large owner Guines Llc bought $28,782 worth of shares (8,801 units at $3.27) (SEC Form 4)

      4 - biote Corp. (0001819253) (Issuer)

      4/23/25 4:58:23 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Craig Hallum initiated coverage on biote Corp.

      Craig Hallum initiated coverage of biote Corp. with a rating of Buy

      12/16/24 8:50:55 AM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • B. Riley Securities initiated coverage on biote Corp. with a new price target

      B. Riley Securities initiated coverage of biote Corp. with a rating of Buy and set a new price target of $9.00

      2/20/24 6:47:29 AM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Jefferies initiated coverage on biote Corp.

      Jefferies initiated coverage of biote Corp. with a rating of Buy

      2/1/24 6:18:15 AM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $BTMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Barrera Richard R

      4 - biote Corp. (0001819253) (Issuer)

      6/11/25 6:54:32 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Morris Debra L converted options into 11,045 shares, increasing direct ownership by 28% to 50,155 units (SEC Form 4)

      4 - biote Corp. (0001819253) (Issuer)

      5/15/25 11:26:51 AM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by Director Heyer Steven J

      4 - biote Corp. (0001819253) (Issuer)

      5/14/25 7:42:41 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care